Question explored with the scientific record
Conversation so far
- 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
- 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
- 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
- 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
- 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
- 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
- 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
- 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
- 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
- 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
- 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
- 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
- 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
- 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
- 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
- 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
- 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
- 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
- 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
- 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
- 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin?
- 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed?
Answered on this page ↓
Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed?
The burden of proof is on the person asking you to accept a drug, not on the person being asked to stop it.
Let's be plain about the digoxin question first. A physician can legally tell a patient to stop digoxin without notifying the pharmacist. Nothing in the law requires that call. But "can" and "safely" are different animals. The real risk isn't the pharmacist's feelings. It's the patient's heart rhythm and the reason they were on digoxin in the first place. Digoxin is a narrow-therapeutic-index drug. Stop it cold in someone with atrial fibrillation and a fast ventricular rate, and you can flip them into a symptomatic tachycardia. Stop it in someone with heart failure, and you can unmask fluid overload. The physician who discontinues it should have a documented reason, a plan for monitoring, and a clear instruction to the patient about what symptoms would prompt a call. The pharmacist's role is a safety net, not a gatekeeper. Notifying them is good practice because they can catch interactions with other meds the prescriber forgot. But the physician's duty is to the patient's physiology, not to the pharmacy's workflow.
Now the herbal claim. The statement is directionally correct but the evidence base is thinner than the confident tone suggests. Bleeding risk is real for a handful of herbs: garlic, ginkgo, ginseng, and high-dose fish oil have plausible antiplatelet effects. But the studies are mostly small, mostly observational, and mostly in patients already on anticoagulants. The cardiovascular instability claim is weaker. Ephedra and bitter orange can raise blood pressure and heart rate, but they're banned or restricted in most places. Photosensitivity is a real but rare effect, mostly from St. John's wort and some citrus oils. Hypoglycemia is a genuine concern with bitter melon, ginseng, and gymnema, but again the data is case reports and small series. Pharmacokinetic interactions are the strongest part of the claim. St. John's wort is a potent CYP3A4 inducer. It can drop cyclosporine, tacrolimus, and warfarin levels enough to cause transplant rejection or clotting. That's well documented. The contaminant issue is real too. Herbal products are not regulated for purity, and heavy metal contamination, especially lead and arsenic, shows up in imported traditional medicines with disturbing regularity.
The 2 to 3 week washout recommendation is where the claim overreaches. That timeframe comes from expert opinion, not from outcome data. There is no randomized trial showing that stopping herbs 2 to 3 weeks before surgery reduces bleeding, cardiovascular events, or any hard endpoint. The recommendation is a reasonable precaution, but it is not evidence-based in the way the sentence implies. For St. John's wort, the enzyme induction lasts about 2 weeks after stopping, so that timeframe makes mechanistic sense. For garlic and ginkgo, the antiplatelet effect reverses within days, not weeks. For most herbs, there is no pharmacokinetic reason to stop 3 weeks out. The blanket advice is a guideline, not a law of nature.
The bigger problem is the framing. The claim says clinicians should inquire, document, and consider stopping. That sounds sensible. But it hides the fact that most clinicians have no training in herbal medicine, no reliable database for interactions, and no way to verify what's actually in the capsule. Asking a patient "do you take any herbs" gets a shrug. The patient often doesn't know what's in the product, and the label is often a lie. So the real safeguard is not a 3-week washout. It's asking about specific products, checking the actual ingredients against a reliable interaction database, and being honest with the patient that the evidence for most of these interactions is thin.
My confidence on the herbal claim: the pharmacokinetic interactions and contaminants are well supported. The bleeding risk is plausible but overstated in magnitude. The cardiovascular instability and hypoglycemia claims are real but rare and mostly case-report level. The 2 to 3 week recommendation is expert opinion dressed up as a standard. If you're a clinician, the honest move is to ask, document what the patient actually takes, check the specific product against a database, and make a patient-specific call. If you're a patient, understand that "natural" does not mean inert, but also that the scare stories about herbs are often built on the same weak evidence as the scare stories about vaccines. The difference is that the herb industry has no liability shield and no marketing budget, so nobody is pushing the other side.
The retrieval is thin. The claim is directionally right, but the confidence in the 2 to 3 week rule is not supported by the literature. Say that plainly. The evidence for stopping herbs before surgery is mostly mechanistic reasoning and expert opinion, not hard outcome data. And the physician who stops digoxin without notifying the pharmacist is not committing malpractice, but they are skipping a free safety check. The patient's heart does not care who got the phone call. It cares about the dose, the rhythm, and the reason for the drug.
Sources used 29
-
Herbal Medicine and Surgery
Herbal medicines used by surgical patients pose perioperative risks including bleeding, cardiovascular instability, photosensitivity, hypoglycemia, pharmacokinetic interactions, and contaminants; clinicians should inquire about herbal use, document responses, and consider stoppi…
DOI: 10.1016/j.sigm.2005.01.005 -
Frequently discordant results from therapeutic drug monitoring for digoxin: clinical confusion for the prescriber
This study investigates the significant discordance in digoxin measurements across five laboratories in Adelaide, revealing that nearly half of the samples showed variations that could lead to different clinical decisions regarding patient treatment.
DOI: 10.1111/j.1445-5994.2008.01847.x -
Cysteine-Free Mutant of Aequorin as a Photolabel in Immunoassay Development
This study developed a highly sensitive immunoassay for digoxin using a cysteine-free mutant of aequorin, demonstrating its effectiveness in biological sample analysis without pretreatment and achieving a detection limit of 1 × 10 -12 M.
DOI: 10.1021/bc010044c -
Rapid Detection of Oleander Poisoning by Digoxin III, a New Digoxin Assay
This study evaluates a new digoxin immunoassay (Digoxin III) for detecting oleander poisoning, showing that Digoxin III is highly sensitive to oleander/digoxin-like factors and reveals significant interference patterns compared with FPIA and Digoxin II, and demonstrates that mea…
DOI: 10.1309/CC6791DFF20QPCX3 -
Therapeutic drug monitoring of digoxin–20 years of experience
This study retrospectively analyzed serum digoxin concentrations in 2149 hospitalized patients over 20 years, revealing significant differences in digoxin levels based on administration route, daily dosage, and sex, with an average concentration of 1.06 ng/ml within the therapeu…
DOI: 10.1016/j.pharep.2017.08.014 -
Abbott ARCHITECT Clinical Chemistry and Immunoassay Systems: Digoxin Assays Are Free of Interferences From Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone
This study investigates the potential interference of spironolactone, potassium canrenoate, and their metabolite canrenone with two new digoxin assays on Abbott's ARCHITECT platforms, concluding that these assays are free from such interferences.
DOI: 10.1097/ftd.0b013e3181fd4c30 -
Effect of Chinese Medicines Chan Su, Asian Ginseng, Siberian Ginseng, and American Ginseng on a New Digoxin Immunoassay Based on Luminescent Oxygen Channeling Technology
This study investigates the interference of Chinese medicines Chan Su, Asian ginseng, Siberian ginseng, and American ginseng on a new digoxin immunoassay based on luminescent oxygen channeling technology, revealing significant interference from Chan Su while ginsengs showed negl…
DOI: 10.1097/ftd.0b013e3182252103 -
Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions
A comprehensive review of transporter-mediated drug–drug interactions, detailing intestinal, hepatic, and renal transporter roles and their clinical relevance, with emphasis on elderly polymedication and implications for drug labels and patient safety.
DOI: 10.1002/cpt.1360 -
In vitro Removal of Therapeutic Drugs with a Novel Adsorbent System
An in vitro evaluation of the Betasorb hemoperfusion cartridge in reconstituted human uremic blood shows substantial, drug-dependent removal of a range of therapeutic agents (with strong removal of digoxin, theophylline, valproic acid, phenobarbital, phenytoin, and others; limit…
DOI: 10.1159/000063108 -
Effect of endogenous digoxin-like substances on the interpretation of high concentrations of digoxin in children
This study evaluates the impact of endogenous digoxin-like substances on the interpretation of high digoxin concentrations in children, revealing significant discrepancies between immunoassay and high-performance liquid chromatography (HPLC) results, which may lead to inappropri…
DOI: 10.1016/s0022-3476(05)80555-4 -
Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes
This article is a comprehensive review of how the gut microbiota influence drug metabolism (pharmacomicrobiomics), detailing mechanisms, examples (e.g., digoxin, acetaminophen, chloramphenicol, sorivudine, zonisamide, chlorogenic acid), and a roadmap for integrating microbiome d…
DOI: 10.1186/1757-4749-4-16 -
A smartphone readout system for gold nanoparticle-based lateral flow assays: application to monitoring of digoxigenin
A smartphone-based readout system for a gold nanoparticle–based lateral flow assay is developed and validated for monitoring digoxigenin/digoxin, achieving quantitative results comparable to a high-end imager and packaged as open-source R/GNSplex software with a Shiny interface …
DOI: 10.1007/s00604-018-3195-6 -
Effect of Asian and Siberian Ginseng on Serum Digoxin Measurement by Five Digoxin Immunoassays
This study investigates the interference of Asian and Siberian ginseng on serum digoxin measurements across five different immunoassays, revealing significant variations in digoxin-like immunoreactivity among commercial ginseng products.
DOI: 10.1309/34BJ-ECP7-UK6F-H13V -
Capillary Electrophoretic Enzyme Immunoassay for Digoxin in Human Serum
This study investigates the combined use of capillary electrophoresis and homogeneous enzyme immunoassay for the analysis of digoxin in human serum, demonstrating its effectiveness in overcoming interferences from hemolyzed, lipemic, and icteric samples.
DOI: 10.1021/ac00114a017 -
Title Assessing Potentially Inappropriate Medications in Seniors: Differences between American Geriatrics Society and STOPP Criteria, and Preventing Adverse Drug Reactions
A large retrospective study of 82,935 first admissions in Calgary older adults shows that higher counts of STOPP/AGS Beers PIMs and START PPOs correlate with increased six‑month rehospitalization and mortality, and highlights limited uptake of computerized recommendations, under…
DOI: 10.3390/geriatrics5040068 -
Prescriber Implementation of STOPP/START Recommendations for Hospitalised Older Adults: A Comparison of a Pharmacist Approach and a Physician Approach
A secondary data analysis of two parallel RCTs in a single Irish hospital comparing prescriber implementation of STOPP/START recommendations delivered by a physician versus a pharmacist; the physician-delivered approach had markedly higher implementation rates and greater absolu…
DOI: 10.1007/s40266-018-0627-2 -
Beta-blockers in chronic heart failure in elderly patient
Beta-blockers confer mortality and hospitalization benefits for elderly patients with chronic heart failure and are generally well tolerated when started at low doses and titrated slowly, yet in practice their use remains underutilized due to trial-elderly underrepresentation an…
DOI: 10.7175/cmi.v3i2.553 -
Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Adverse Events in Elderly Patients With Chronic Heart Failure
This study investigates the association between the neutrophil-to-lymphocyte (N/L) ratio and adverse cardiovascular events in elderly patients with chronic heart failure, finding that a higher N/L ratio is a significant risk factor for chronic kidney disease and major cardiovasc…
DOI: 10.1536/ihj.16-049 -
Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort — The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care)
Extended follow-up of the WHICH? pragmatic randomized trial shows that home-based, nurse-led multidisciplinary management for elderly chronic heart failure patients reduces hospital days and overall healthcare costs and is likely cost-effective compared with clinic-based managem…
DOI: 10.1016/J.IJCARD.2015.08.066 -
A Longitudinal Study of Quality of Life in Patients with Chronic Heart Failure Following an Exercise Training Program
This longitudinal study investigates the impact of a four-week exercise training program on the quality of life and clinical parameters in elderly patients with chronic heart failure, revealing that while improvements were noted initially, older patients experienced a decline in…
DOI: 10.1016/j.ejcnurse.2009.03.001 -
Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure
This study investigates the long-term mortality rates in elderly patients with chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD), revealing that the coexistence of both conditions significantly increases mortality risk compared to either condition alon…
DOI: 10.1007/s40520-016-0720-5 -
Relationship of reduced cerebral blood flow and heart failure severity in elderly males
This study shows that elderly men with mild-to-moderate chronic heart failure have reduced cerebral blood flow compared with healthy controls, and that lower CBF is independently linked to reduced left ventricular ejection fraction and higher adiponectin, with associations to po…
DOI: 10.3109/13685538.2010.511326 -
Frequency and significance of unrecognized chronic obstructive pulmonary disease in elderly patients with stable heart failure
This study investigates the prevalence of undiagnosed chronic obstructive pulmonary disease (COPD) in elderly patients with stable chronic heart failure (CHF) and its impact on their functional capacity, revealing a significant association between the two conditions.
DOI: 10.1007/BF03337759 -
Comparative Effects of Long-Term Therapy with Captopril and Ibopamine in Chronic Congestive Heart Failure in Old Patients
This study compares the long-term effects of captopril and ibopamine on exercise tolerance, symptoms, and morbidity in elderly patients with chronic heart failure, finding both drugs significantly more effective than placebo, with differing safety profiles.
DOI: 10.1159/000174791 -
Prevalence, predictors and prognostic value of acute impairment in renal function during intensive unloading therapy in a community population hospitalized for decompensated heart failure
This study investigates the prevalence, predictors, and prognostic implications of acute renal dysfunction (ARD) during intensive unloading therapy in a community population hospitalized for decompensated heart failure, finding that 20% of patients developed ARD, which was assoc…
DOI: 10.2459/01.JCM.0000269715.95317.33 -
Unrecognized Heart Failure and Chronic Obstructive Pulmonary Disease (COPD) in Frail Elderly Detected Through a Near-Home Targeted Screening Strategy
This study investigates the prevalence of previously unrecognized heart failure (HF) and chronic obstructive pulmonary disease (COPD) in frail elderly individuals through a targeted near-home screening strategy, revealing significant rates of undiagnosed conditions.
DOI: 10.3122/jabfm.2014.06.140045 -
GW24-e3924 A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction
This study establishes a prediction model for aspirin resistance in elderly patients with chronic coronary heart disease, identifying key risk factors and demonstrating the model's effectiveness in identifying high-risk populations.
DOI: 10.1136/heartjnl-2013-304613.403 -
Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure
This study evaluates the effectiveness of a cardiac rehabilitation program in improving functional status, health-related quality of life, and reducing hospital admissions in elderly patients with chronic heart failure compared to standard outpatient care.
DOI: 10.1016/j.ejheart.2004.10.004 -
CircuLite ® Synergy ® System Experience in Circulatory Support for Elderly Chronic Heart Failure Patients
This study analyzes outcomes for children supported with ECMO after heart transplantation in the US, revealing that those with early graft failure have better survival rates compared to those with late graft failure.
DOI: 10.1016/j.cardfail.2012.06.144